[go: up one dir, main page]

WO2006131649A3 - Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones - Google Patents

Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones Download PDF

Info

Publication number
WO2006131649A3
WO2006131649A3 PCT/FR2006/001297 FR2006001297W WO2006131649A3 WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3 FR 2006001297 W FR2006001297 W FR 2006001297W WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioavailability
increase
fumagillin
derivatives
macrocyclic lactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/001297
Other languages
French (fr)
Other versions
WO2006131649A2 (en
Inventor
Michel Alvinerie
Jacques Dupuy
Anne Lespine
Jean-Francois Sutra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to EP06764749A priority Critical patent/EP1888116A2/en
Priority to BRPI0611642-6A priority patent/BRPI0611642A2/en
Priority to AU2006256616A priority patent/AU2006256616A1/en
Priority to CA002611201A priority patent/CA2611201A1/en
Priority to US11/917,031 priority patent/US20080200402A1/en
Priority to MX2007015504A priority patent/MX2007015504A/en
Publication of WO2006131649A2 publication Critical patent/WO2006131649A2/en
Publication of WO2006131649A3 publication Critical patent/WO2006131649A3/en
Anticipated expiration legal-status Critical
Priority to US12/975,410 priority patent/US20110144045A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of fumagillin and the analog derivatives thereof, as inhibitors of cellular transporters, such as ABC transporters, and especially of P-glycoprotein, in order to increase the bioavailability of active ingredients that can be used in the treatment of pathologies such as cancers or parasitic diseases, and especially in order to increase the bioavailability of the macrocyclic lactones.
PCT/FR2006/001297 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones Ceased WO2006131649A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06764749A EP1888116A2 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
BRPI0611642-6A BRPI0611642A2 (en) 2005-06-08 2006-06-08 use of fumagillin and its derivatives to increase the bioavailability of macrocyclic lactones
AU2006256616A AU2006256616A1 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
CA002611201A CA2611201A1 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
US11/917,031 US20080200402A1 (en) 2005-06-08 2006-06-08 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones
MX2007015504A MX2007015504A (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones.
US12/975,410 US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0505829 2005-06-08
FR0505829A FR2886855B1 (en) 2005-06-08 2005-06-08 USE OF FUMAGILLIN AND ITS DERIVATIVES TO INCREASE BIODAVAILABILITY OF MACROCYLIC LACTONES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/975,410 Division US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Publications (2)

Publication Number Publication Date
WO2006131649A2 WO2006131649A2 (en) 2006-12-14
WO2006131649A3 true WO2006131649A3 (en) 2007-06-21

Family

ID=35064492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001297 Ceased WO2006131649A2 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Country Status (9)

Country Link
US (2) US20080200402A1 (en)
EP (1) EP1888116A2 (en)
AU (1) AU2006256616A1 (en)
BR (1) BRPI0611642A2 (en)
CA (1) CA2611201A1 (en)
FR (1) FR2886855B1 (en)
MX (1) MX2007015504A (en)
WO (1) WO2006131649A2 (en)
ZA (1) ZA200710600B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009374A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
KR20120083905A (en) 2009-10-09 2012-07-26 자프겐 코포레이션 Sulphone compounds for use in the treatment of obesity
JP5827239B2 (en) 2010-01-08 2015-12-02 ザフゲン，インコーポレイテッド Fumagillol type compound and method for producing and using the same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
BR112013013411A2 (en) 2010-11-29 2016-09-13 Zafgen Inc obesity treatment using non-daily administration of 6-0- (4-dimethylaminoethyl) cinnamoyl fumagilol
KR20140006888A (en) 2011-01-26 2014-01-16 자프겐 인크. Tetrazole compounds and methods of making and using same
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
US9351988B2 (en) 2011-05-02 2016-05-31 Universite De Geneve Macrocyclic lactones and use thereof
JP5941981B2 (en) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド Tricyclic sulfonamide compounds and methods for their production and use
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014008706A (en) 2012-01-18 2015-03-05 Zafgen Inc Tricyclic sulfonamide compounds and methods of making and using same.
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
KR20150013222A (en) 2012-05-08 2015-02-04 자프겐 인크. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EA028367B1 (en) 2012-11-05 2017-11-30 Зафджен, Инк. Methods of treating liver diseases
KR20150080614A (en) 2012-11-05 2015-07-09 자프겐 인크. Tricyclic compounds for use in the treatment and/or control of obesity
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
ES2955137T3 (en) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Fumarate prodrugs and their use in the treatment of various diseases
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
TW201636342A (en) 2014-12-19 2016-10-16 武田藥品工業有限公司 Nicotinic acid derivative
CN106432255A (en) 2015-08-11 2017-02-22 扎夫根公司 Fumigillol spiro-compound, preparation and use method thereof
AR105671A1 (en) 2015-08-11 2017-10-25 Zafgen Inc HUMEROCYCLIC COMPOUNDS OF FUMAGILLOL AND ITS METHODS OF ELABORATION AND USE

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
EP0658342A1 (en) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Antineoplastic pharmaceutical composition containing a fumagillol derivative
WO1996030010A2 (en) * 1995-03-27 1996-10-03 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
EP1258248A2 (en) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
WO2004039172A1 (en) * 2002-10-31 2004-05-13 Szoke Annamaria Oral veterinary drug delivery system and/or feed additive delivery system, process for the preparation and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
EP0658342A1 (en) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Antineoplastic pharmaceutical composition containing a fumagillol derivative
WO1996030010A2 (en) * 1995-03-27 1996-10-03 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
EP1258248A2 (en) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
WO2004039172A1 (en) * 2002-10-31 2004-05-13 Szoke Annamaria Oral veterinary drug delivery system and/or feed additive delivery system, process for the preparation and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRINYAEV V A ET AL: "Antitumor effect of avermectins", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 19 - 23, XP004587589, ISSN: 0014-2999 *
LESPINE A ET AL: "Role of the p-glycoprotein in the cellular efflux of macrocyclic lactones: Influence of interfering agents.", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 26, no. Supplement 1, August 2003 (2003-08-01), & PROCEEDINGS OF THE 9TH INTERNATIONAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR VETERINARY PHARMACOLOG; LISBON, PORTUGAL; JULY 13-18, 2003, pages 161 - 162, XP008077611, ISSN: 0140-7783 *
WILHELMUS K R: "Antiparasitic drugs in ophthalmology", INTERNATIONAL OPHTHALMOLOGY CLINICS 1996 UNITED STATES, vol. 36, no. 2, 1996, pages 117 - 152, XP008077587, ISSN: 0020-8167 *

Also Published As

Publication number Publication date
FR2886855A1 (en) 2006-12-15
FR2886855B1 (en) 2009-07-17
ZA200710600B (en) 2009-05-27
BRPI0611642A2 (en) 2010-09-28
AU2006256616A1 (en) 2006-12-14
EP1888116A2 (en) 2008-02-20
CA2611201A1 (en) 2006-12-14
US20080200402A1 (en) 2008-08-21
MX2007015504A (en) 2008-03-18
US20110144045A1 (en) 2011-06-16
WO2006131649A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2006131649A3 (en) Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
PL1940249T3 (en) Novel formulations of fat-soluble active ingredients with high bioavailability
EP2450360A3 (en) (S)-N-Methylnaltrexone
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2007086001A3 (en) Novel pyridine derivatives
IL174154A (en) Glp-1 derivatives, pharmaceutical compositions comprising them and their use in manufacturing medicaments
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2005123076A3 (en) Pharmaceutical compositions
WO2006099169A3 (en) Novel liposome compositions
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2006060515A3 (en) System for improved percutaneous absorption of skin benefiting agents
WO2009038095A1 (en) Composition comprising sesamin component and vitamin b1 component
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
WO2009059755A3 (en) Novel neurturin conjugates for pharmaceutical use
WO2006021001A3 (en) Amphiphilic polynorbornene derivatives and methods of using the same
WO2006075256A3 (en) 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
AU2003290127A1 (en) 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
SI1646378T1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
WO2007114946A3 (en) Acid-sensitive linkers for drug delivery
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
WO2008037740A3 (en) Beverage suitable to retard the cellular degeneration which accompanies ageing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015504

Country of ref document: MX

Ref document number: 2611201

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 564101

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11917031

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611642

Country of ref document: BR

Kind code of ref document: A2